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Abstract: The pivotal role of hepatic stellate cells (HSCs) in orchestrating the bidirectional process of
progression and regression of liver fibrosis makes them an ideal target for exploring new antifibrotic
therapies. Essential phospholipids (EPLs), with their polyenylphosphatidylcholine (PPC) fraction,
either alone or combined with other hepatoprotective substances such as silymarin, are recommended
in hepatic impairment, but a scientific rationale for their use is still lacking. Herein, we compared the
ability of EPLs to restore quiescent-like features in HSCs with that of dilinoleoylphosphatidylcholine
(DLPC), PPC fraction’s main component. Specifically, we screened at the cellular level the antifibrotic
e↵ects of PPC formulations in the presence and absence of silymarin, by using LX-2 cells (pro-fibrogenic
HSCs) and by assessing the main biochemical hallmarks of the activated and deactivated states of this
cell line. We also proved the formulations’ direct e↵ect on the motional order of cell membranes of
adherent cells. LX-2 cells, examined for lipid droplets as a quiescence marker, showed that PPCs led
to a more prominent deactivation than DLPC. This result was confirmed by a reduction of collagen
and ↵-SMA expression, and by a profound alteration in the cell membrane fluidity. PPC–silymarin
formulations deactivated HSCs with a significant synergistic e↵ect. The remarkable bioactivity of
PPCs in deactivating fibrogenic HSCs paves the way for the rational design of new therapeutics
aimed at managing hepatic fibrosis.
Keywords: liver fibrosis; essential phospholipids; hepatic stellate cells; liposomes; silymarin;
antifibrotic; reversion; quiescent; inactivation
1. Introduction
Liver fibrosis is the formation of a pathological amount of scar tissue in the liver due to an increased
deposition of extracellular matrix (ECM) proteins in response to chronic injuries [1]. Although the
release of ECMproteins is an essential part of the wound-healing response, repeated injuries, as occur in
most type of chronic liver diseases (e.g., chronic hepatitis B and C, metabolic disorders, or non-alcoholic
fatty liver disease (NAFLD)), promote fibrosis [2]. Advancement of the disease distorts the normal liver
parenchyma, resulting in cirrhosis and ultimately compromising liver functionality irreversibly [2].
Hepatic fibrosis usually commences unobserved, and most of the related mortality and morbidity
occur after the development of cirrhosis [3]. Chronic liver diseases, with more than 800 million people
a↵ected worldwide, represent a major concern for public health [4]. Globally, the mortality rate is
approximately 2 million per year due to related complications [3]. Indeed, cirrhosis and liver cancer
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account for 3.5% of all deaths worldwide, making them the 11th and 16th most common causes of
death each year, respectively [5]. The hepatic fibrosis stage is the most important determinant of patient
mortality [6], yet to date, there is an unmet medical need for e↵ective anti-fibrotic treatments [7–9].
Tissue fibrogenesis was long thought to be a unidirectional, progressive process, but it was
found to be potentially reversible when the provoking event is treated or resolved [10]. Although the
underlying trigger for fibrosis development is multicausal [2], hepatic stellate cells (HSCs) have been
identified as the central disease mediators, as well as the major fibrogenic cell type in liver fibrosis [11].
As a result of chronic hepatic injury, HSCs undergo a complex phenotypic transdi↵erentiation known as
“activation”, responsible for a cell transition from a quiescent status to a fibrogenic, highly proliferative,
myofibroblast-like status [11,12]. Quiescent HSCs are characterized by an abundance of cytoplasmic
lipid droplets used to store the majority of retinoid present in the body [13]. Activated HSCs
experience a loss of lipid droplets, resulting in reduced retinoid storage, an increased ECM protein
production (e.g., collagen type I), and an enhanced contractility accompanied by an elevated expression
of cytoskeleton filaments (e.g., ↵-smooth muscle actin (↵-SMA)) [13–15]. Interestingly, previous
studies have established that activated HSCs can undergo apoptosis or reversion to a quiescence-like
phenotype [16]. However, the upstream endogenous processes that direct myofibroblasts towards
reversion or death are not clear. Progress in gaining insight into this pathogenesis has been made
also through the use of immortalized human HSCs (LX-2 cells). LX-2 cells greatly retain key features
of activated human HSCs, including retinoid metabolism and fibrogenesis [17]. This cell line can be
quiesced or perpetuated in activation [1,11,15,18], providing an important tool to study themechanisms
of action of antifibrotic compounds [19]. The HSCs’ pivotal role in liver fibrosis, their ability to reverse
to quiescence, and their easily accessible location in the space of Disse, between blood vessels and
hepatocytes, make these cells an important therapeutic target for the disease [2,20].
At present, no e↵ective anti-fibrogenic therapy is available. Since the late 90s, administration
of essential phospholipids (EPLs), highly purified extracts of soybeans, has been an approach for
the management of fatty liver disease, due to their supposedly antioxidant and anti-inflammatory
action [21]. However, the exact mechanism through which EPLs exert their beneficial hepatoprotectant
e↵ect is still unknown [21,22]. EPLs are >72% composed of a mixture of polyenylphosphatidylcholines
(PPCs), in which 1,2-dilinoleoylphosphatidylcholine (DLPC) is the quantitatively dominant lipid [21].
Phospholipids are generally recognized as safe (GRAS) excipients of the Federal Food, Drug, and
Cosmetic Act, and are characterized by high bioavailability [23]. In Eastern European countries, EPLs
are recommended for people with non-alcoholic steatohepatitis (NASH) [22], and in 2017, EPLs alone
and combined with other active ingredients (e.g., herbal preparation, vitamins) accounted for 46.9% of
the hepatoprotective drug market in Russia [22]. Products such as Livolin®, Essenvita®, or Essentiale®
are indicated as nutritional support in the management of liver fatty degeneration, hepatitis (caused by
toxins, medicines, or alcohol abuse), or cirrhosis. Among all hepatoprotective substances incorporated
into EPL formulations, silymarin is one of the most frequently investigated [24]. The therapeutic
action of the lipophilic extract from the seeds of Silybum marianum, collectively known as silymarin, in
chronic liver disease seems to be related to a reduction of HSC activation in primary culture, along
with inhibition of proinflammatory cytokine production and antioxidant e↵ects [25]. Recent evidence
highlights silymarin’s inhibitory e↵ect on LX-2 cells fibrogenic gene expression [26]. SILIPHOS®,
Hepatrine®, and Karsil® are three examples of commercially available silymarin-based products.
However, to our knowledge, a systematic investigation on the antifibrogenic e↵ect of a combination
between PPC and silymarin screened at a cellular level has not been carried out to date.
Controversially, the exact mechanism of the hepatoprotective action of PPCs, attributed to DLPC,
the pivotal component of PPCs [21,27], remains unclear in humans, and more rigorous clinical trials
are required to determine the benefits in liver fibrosis. Studies have documented PPCs to be protective
against liver damage caused by chronic alcohol consumption in patients with hepatitis B [21] or
primates with fibrosis [28], and against non-alcoholic hepatic fibrosis induced by fat diet, albumin,
or carbon tetrachloride (CCl4) in rats [29,30]. One animal study in rats also demonstrated that EPLs
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alleviate the accumulation of fat in the steatosis induced by orotic acid [31]. PPC-based treatments
resulted in a reduced accumulation of collagen in the culture media of rat acetaldehyde-activated HSCs
as a model for alcoholic disease [32]. The involved mechanisms could be in part attributed to DLPC
stimulation of collagenase activity, responsible for the breakdown of collagen [33,34]. Other studies
have also reported PPC-mediated suppression of collagen and ↵-SMA expression in human HSCs by
showing reduced levels of reactive oxygen species induced by TGF- 1 [35]. PPCs have been reported to
possess an intriguing ability to incorporate into damaged sections of hepatic cell membranes, helping
to maintain membrane fluidity and function [36]. PPC supplementation is correlated, among other
e↵ects, with amelioration of ethanol-induced decreases in membrane-bound enzyme activities (e.g.,
phosphatidylethanolamine methyltransferase) and with an adjustment of phospholipid depletion [37].
This could be one of the mechanisms through which PPCs exert their antifibrotic e↵ect. However,
studies on PPCs in hepatic fibrosis to date do not permit an optimization of EPL’s therapeutic utility in
liver fibrosis because of the lack of long-term controlled clinical trials aimed at determining their precise
benefit (e.g., for inducing histological changes, alleviating symptoms, and slowing the progression
of the disease). A comprehensive, standardized knowledge of their role in liver fibrosis and their
mechanism of action on human HCSs is still missing.
The aim of this study was to provide a quantitative assessment at the cellular level of the
antifibrotic potential of various phospholipid-based drug formulations in an in vitro model of hepatic
fibrosis. Specifically, we chose a dynamic fibrogenic cell model of human HSCs that can be either
quiesced, or further activated and then reverted to the quiescent-like status. By means of this HSC
transdi↵erentiation model, the antifibrotic properties of PPC-based formulations were evaluated.
To gain a better understanding of PPCs’ mechanism of action, a PPC-rich (>75%) lipid, S80, and
its corresponding complexes with MgCl2 and CaCl2 salts (SMg and SCa, respectively) were formulated
as liposomes, tested on HSCs, and compared. Furthermore, formulations of either DLPC, DOPC,
or DOPC/DLPC, mirroring the DLPC content in the employed PPC-rich lipids, were investigated.
Additionally, the coadjuvant e↵ect of the hepatoprotectant silymarin co-formulated with PPC was
studied. In order to define the molecular mechanism underpinning the antifibrotic e↵ect of PCCs, we
tested the expression level of lipid droplets and that of main fibrotic markers (i.e., ↵-SMA, collagen). We
finally made innovative use of fluorescence anisotropy to study the motional order of cell membranes
of living LX-2 cells.
2. Materials and Methods
2.1. Materials
Soybean phospholipid with 75% phosphatidylcholine (S80), soybean phospholipid 80%
complexed with MgCl2 (S 80 M; SMg), soybean phospholipid 80% complexed with CaCl2 (S 90;
SCa), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were a kind gift from Lipoid GmbH
(Ludwigshafen, Germany). Their fatty acid content is available in the Supporting Information
(Table S1). 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) was purchased from Avanti Polar
Lipids (Alabaster, AL, USA). Membranes for liposome extrusion were from Whatman® NucleoporeTM
(Maidstone, UK). The LX-2 cells immortalized human hepatic stellate cell line, Dulbecco’s Modified
Eagle Medium (DMEM) (4.5 g/L glucose, with phenol red, no glutamine, no sodium pyruvate),
penicillin/streptomycin mixture (penicillin: 10,000 U/mL, streptomycin: 10,000 µg/mL), l-glutamine
(200 mM), fetal bovine serum (FBS), Accutase®, and TGF- 1 were purchased from Merck Millipore
(Darmstadt, Germany). Silymarin, Oil red O (ORO; 0.5%w/v in propylene glycol), retinol (Rol), palmitic
acid (PA), Cell Counting Kit-8 (CCK-8), 4’,6-diamidino-2-phenylindole (DAPI), diphenylhexatriene
(DPH), (1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate) (TMA-DPH),
bovine serum albumin (BSA), and dimethyl sulfoxide (DMSO) were bought from Sigma-Aldrich
(Schnelldorf, Germany). Sirius Red/Fast Green collagen staining was obtained from Chondrex
(Redmond, WA, USA), ↵-smooth muscle actin (↵-SMA) monoclonal antibody, and Alexa Fluor®
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647-labeled goat anti-mouse IgG from Thermo Fisher Scientific (Waltham, MA, USA), and DMEM
(4 mM L-glutamine, 4.5 g/L glucose, with sodium pyruvate, no phenol red) from HyClone (Logan, UT,
USA). Sodium hydrogen phosphate (Na2HPO4), potassium dihydrogen phosphate (KH2PO4), sodium
chloride (NaCl), potassiumchloride (KCl), Roti®-Histofix 4% (acid free, pH7.4%w/vphosphate-bu↵ered
formaldehyde solution), formaldehyde (37% w/v in H2O), chloroform (CHCl3), ethanol (EtOH),
trifluoroacetic acid (TFA), methanol (MeOH), acetonitrile (ACN), acetic acid, and 4-(2-Hydroxyethyl)
piperazine-1-ethanesulfonic acid sodium (HEPES) salts were purchased from Carl Roth (Karlsruhe,
Germany). Cell culture plates were from Greiner Bio One International GmbH (Monroe, NC, USA).
2.2. Development of PPC-Based Formulations
Lipid vesicles containing either synthetic phosphatidylcholines (DOPC, DLPC, or a mixture
DOPC/DLPC (57:43 mol%)) or a natural soybean-derived phospholipid (S80, SMg, or SCa) were
prepared according to the film hydration extrusion method [38]. Briefly, an appropriate aliquot of lipid
stock solution in CHCl3 was evaporated under a stream of nitrogen until dry. Traces of solvent were
further removed by keeping the resulting thin lipid films under vacuum overnight. After hydration
with HEPES bu↵er (10 mM in H2O, pH 7.4), the liposomal formulations (final lipid concentration
50 mM) were extruded 10 times through a 0.2 µm polycarbonate membrane at room temperature
(RT) using a LIPEX® extruder (Transferra Nanosciences Inc., Burnaby, B.C., Canada). Lipids were
quantified chromatographically as detailed in the Supporting Materials and Methods.
2.3. Development of Silymarin PPC-Based Formulations
Silymarin liposomes were produced with S80, SMg, SCa, or DOPC starting from a dry lipid film
(vide supra). Aliquots of methanolic stock solution of silymarin were added to the lipid film to obtain a
final theoretical lipid-to-silymarin ratio of 1:11. After removal of the organic solvent, the resultant lipid
film with silymarin was hydrated with HEPES bu↵er (10 mM, pH 7.4), and the liposomal formulation
was extruded as described in Section 2.2. Lipids and silymarin were quantified as detailed in the
Supporting Materials and Methods.
2.4. Characterization of Particle Size and Size Distribution
The hydrodynamic diameter and the size distribution (polydispersity index, PDI) of the liposomes
were measured with the Zetasizer Nano ZS (Malvern, Worcestershire, UK) with a 173  backscatter
angle and a 633 nm helium–neon laser. The produced liposomes were diluted with MilliQ water to
a concentration of 0.2 mM. The intensity size distribution of the liposomes was typically unimodal;
therefore, the autocorrelation function was analyzed according to the cumulant method.
2.5. Cell Culture and General Design of Cell Experiments
LX-2 cellswere grown at 37  C in a humidified atmosphere containing 5%CO2 in completemedium
(CM): DMEM (4.5 g/L glucose, phenol red, no L-glutamine, no sodium pyruvate) supplemented with
1% v/v penicillin/streptomycin mixture (penicillin: 10,000 U/mL, streptomycin: 10,000 µg/mL), 1%
v/v of L-glutamine (200 nM), and 2% v/v FBS. Subcultivation was performed with Accutase at a cell
confluency of about 80% according to the manufacturer instructions. Cells at passage number 5 to 18
were used for cell experiments.
Cell experiment medium (EM) was serum-free, prepared with DMEM and supplemented with 1%
v/v penicillin/streptomycin and 1% v/v L-glutamine. For the cell proliferation assay, serum-free and
phenol-red-free DMEM supplemented with 1% v/v penicillin/streptomycin was used instead.
For experiments, LX-2 cells were seeded either in 12 well microtiter plates with 1 mL CM/well at a
density of 100,000 cells/well, or in transparent or black 96 well microtiter plates with 100 µL CM/well
at a density of 12,000 cells/well, and cultured 18 h at 37  C, 5% CO2 to 70–90% confluency. Treatments
were always performed with 1 mL/well for 12 well plates or 100 µL/well for 96 well plates at 37  C,
5% CO2.
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2.6. Experimental Approach: Direct Treament of LX-2 Cells and Treatment of Perpetuated LX-2 Cells
(pLX-2 Cells)
After cell seeding, the CM from seeded LX-2 cells was discarded and the cells were rinsed once
with phosphate-bu↵ered saline (PBS). Treatments of LX-2 cells in microtiter plates were then performed
directly on naïve LX-2 cells or after a further activation of LX-2 cells (perpetuated LX-2 cells; pLX-2
cells) obtained with TGF- 1 [12,39,40]. For the direct treatment, the formulations were mixed with EM
and LX-2 cells were incubated with this solution for 24 h, as described below. For the perpetuation,
TGF- 1 in PBS (with 0.1% w/v BSA; 10 µg/mL) was diluted in EM to reach a final TGF- 1 concentration
of 10 ng/mL. LX-2 cells were then treated with this solution for 24 h [41,42]. TGF- 1 was discarded, and
the cells were rinsed once with PBS and then treated as described below. TGF- 1 (10 ng/mL) was also
used as control to induce fibrogenesis in the direct treatment starting from naïve LX-2 cells [12,39,40].
A graphical representation of the experimental approach is depicted in Scheme 1.
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2.7. Induction of Quiescent-Like LX-2 Cells with Retinol and Palmitic Acid (Rol + PA)
LX-2 cells or pLX-2 cells were incubated for 24 h with retinol and palmitic acid (Rol + PA) to
reverse LX-2 cell fibrogenesis (Scheme 1) following previously reported results [43]. Rol + PA stock
solutions were vigorously mixed with EM to reach 10 µM Rol and 300 µM PA. Wells with vehicle
control received equal volumes of EM.
2.8. LX-2 Cells and pLX-2 Cells Treatment with PPC-Based Formulations
Each liposomal formulationwasmixedwith EM to obtain amediumwith 5mM lipid concentration
(LM). LX-2 cells or pLX-2 cells were then incubated with LM for 24 h (Scheme 1) to cover the same
incubation range as Rol + PA and TGF- 1 treatment.
Wells with vehicle control received equal volumes of EM. To assess the antifibrotic e↵ect of the
treatment on the cells, the presence of cytosolic lipid droplets and collagen, as well as the expression of
↵-SMA, were analyzed as described below.
2.9. Analysis of Lipid Droplet Content
After cell treatment, LX-2 cells in 12 well plates were washed three times with PBS, fixed with
500 µL/well Roti®-Histofix 4% for 15 min at RT, and washed once with 1 mL/well deionized MilliQ
water. To avoid artefactual formation of lipid droplets due to ORO solvents such as ethanol and
isopropanol [44], cells were stained with a 0.5% w/v ORO solution in propylene glycol (500 µL/well) for
15 min at RT. The staining was carefully washed o↵ using PBS. Nuclei were then counterstained with a
3.6 µMDAPI solution in PBS for 5 min at RT (300 mL/well). Afterwards, cells were rinsed with PBS
(1 mL/well). Fluorescence and phase contrast image acquisition was performed using a Nikon Ti-U
(Nikon Instruments, Melville, NY, USA) inverted microscope (acquisition details in the Supporting
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Materials and Methods). The fluorescent binary area and the object count were detected with the NIS
Elements (Nikon Instruments, Melville, NY, USA) software v. 5.00 and exported.
2.10. Analysis of Fibrillar Collagen
After cell treatment in 12 well plates, the total protein content and the collagen content were
measured with the Sirius Red/Fast Green collagen staining kit according to the manufacturer’s
instructions. Briefly, LX-2 cells were carefully washed three times with PBS and then fixed for 15
min at RT with a freshly prepared Kahle fixative solution (60 mL distilled H2O, 28 mL 96% v/v EtOH,
10 mL 37% w/v formaldehyde, 2 mL glacial acetic acid) (500 µL/well). After rinsing cells with PBS,
Sirius Red/Fast Green staining solution was added (200 µL/well) and cells were left at RT for 30 min.
The cells were then washed three times with PBS (500 µL/well), fresh PBS was added (1 mL/well), and
bright field images were acquired using a Nikon Ti-U inverted microscope (acquisition details in the
Supporting Materials and Methods).
2.11. Analysis of ↵-SMA Expression
After cell treatment in 12 well plates, cells were washed twice with PBS and then fixed and
permeabilised in 500 µL/well ice-cold MeOH for 30 min at RT. After fixation, cells were washed once
with PBS and incubated with 500 µL/well blocking solution (5% w/v BSA in PBS) for 30 min at RT.
Primary mouse IgG diluted in blocking solution (0.1 µg IgG/mL) was incubated with cells (500 µL/well)
for 18 h at RT. After three washes with blocking solution, cells were incubated with secondary goat
anti-mouse IgG-Alexa Fluor 647 diluted in blocking solution (10 µg/mL) for 2 h at RT (500 µL/well).
Plates were washed three times with PBS, stained with 3.6 µMDAPI solution for 5 min, and washed
again three times with PBS. Fluorescence images acquisition was performed using a Nikon Ti-U
inverted microscope (acquisition details in the Supporting Materials and Methods). The fluorescent
binary area and the object count were detected with the NIS Elements software v. 5.00 and exported.
2.12. Cell Proliferation Assay
The CCK-8 assay was used following the manufacturer’s instruction. Briefly, after treatments
(100 µL/well; 96 well plate), cells were washed twice with PBS. A volume of 90 µL of serum-free and
phenol-red-free DMEM supplemented with 1% v/v penicillin/streptomycin and a volume of 10 µL of
CCK-8 were added to each well. LX-2 cells were incubated for further 2 h at 37  C, 5% CO2. Afterwards,
the absorbance was measured at 450 nm using a plate reader (Spark 10M, Tecan, Switzerland) at 37  C.
The following equation was used to calculate the cell metabolic activity in percent (Equation (1)):
Cell metabolic activity (%) = (OD sample/OD control) ⇥ 100, (1)
where “OD sample” refers to the optical density of the cells treatedwith the substances and “OD control”
is the cells exposed to phenol-red-free DMEM supplemented with 1% v/v penicillin/streptomycin only.
2.13. Motional Order of the Cell Membrane in Adherent LX-2 Cells
DPH and TMA-DPH were dissolved in DMSO to a concentration of 8 and 5 mM, respectively,
and were stored at  20  C, protected from light. DPH and TMA-DPH stock solutions in DMSO and
working solutions of DPH (8 µM) or TMA-DPH (5 µM) in PBS were prepared fresh for each experiment.
After cell treatment (100 µL/well), the cells were washed three times with PBS and 100 µL of DPH-PBS
(8 µM) or TMA-DPH-PBS (5 µM) were added to each well of the 96 well plate (black bottom and wall).
LX-2 cells were then further incubated for either 2 h at 37  C, 5% CO2 with DPH–PBS, or for 10 min at
37  C, 5% CO2 with TMA-DPH–PBS. After one PBS wash (100 µL/well), all of the remaining solution
was aspirated from the wells. The fluorescent anisotropy was measured with a Tecan’s Spark 10M
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plate reader equipped with polarization filters (monochromator mode,  ex = 360 nm,  em = 430 nm)
and calculated by applying the following formula (Equation (2)):
r =
G⇥ Ik   I?
G⇥ Ik + 2I? , (2)
where Gwas 1.678 for DPH and 1.559 for TMA-DPH.
2.14. Statistical Analysis
All experiments were performed in at least three independent replicates, and samples were freshly
prepared if not stated otherwise.
One-way ANOVA analysis of variance was used to compare means of independent experiments.
Significant di↵erences in lipid droplets quantification, ↵-SMA expression, and motional order of cell
membrane among treatments were compared by Tukey’s multiple comparisons test (**** p  0.0001,
*** p  0.001, ** p  0.01, *p  0.05). Data are presented as mean ± S.D (standard deviation calculated
from independent samples).
3. Results and Discussion
3.1. Progression and Regression of Fibrogenic Features in LX-2 Cells
As previously described (Scheme 1), in our study cells were treated with TGF- 1 and Rol + PA
in order to thoroughly investigate the progression and regression of LX-2 cells’ fibrogenic feature.
The results were in agreement with the expected behavior of activated and quiescent-like HSCs,
respectively [39,40,43,45].
Upon treatment with Rol + PA, LX-2 cell proliferation was inhibited in accordance with previous
results [45,46], while for LX-2 cell perpetuation, the exposure to 10 ng/mL TGF- 1, a major fibrogenic
cytokine in liver disease, resulted in a typical increase in cell proliferation (Figure S1) [47].
After assaying the metabolic activity, the in vitro model was characterized by monitoring lipid
droplet storage along with collagen and ↵-SMA expression as key markers. Although the use of free
fatty acids (i.e., palmitic acid, or a mixture palmitic/oleic acid) can result in the activation of HSCs
grown in monoculture or in simultaneous co-culture with hepatocytes [48,49], it has been reported that
palmitic acid or oleic acid supplemented with retinol significantly induce changes in lipid droplets
and promote the reversion of activated HSCs [50]. In a previous study, the enlarged droplets obtained
with retinol and oleic acid treatments resulted in the recruitment of ATG2A protein to downregulate
autophagy and reverse the activation of LX-2 cells [50]. The presence of lipid droplets in HSCs is
notably influenced by dietary retinol intake [51,52]. Generally, retinol binds cellular retinol-binding
proteins (CRBPs), and it is converted to retinyl esters by the retinol acyltransferase (LRAT) [53]. In the
activated state, retinol is also oxidized to retinoic acid which binds to Rar↵ proteins, upregulating the
expression of CRBPs, and therefore increasing the esterification process [53].
In our study, the combination of Rol and PA stimulated the formation of lipid droplets by an
upregulation of the adipose di↵erentiation-related (ADRP) protein, indicating LX-2 cell quiescence, as
well evidenced in an earlier research [43]. Within the evaluated time frame, Rol + PA treatment induced
a rise in the number of lipid droplets visible as brown spots in bright field and red spots in fluorescence
images in comparison to what was observed in untreated LX-2 cells (EM) or TGF- 1-treated cells
(Figure 1a).
Beside the qualitative interpretation, the quantitative analysis of fluorescence in imagesmaximized
the amount of information extracted and enabled a more transparent observation of the di↵erent
treatment e↵ects on LX-2 cells. A similar analysis was previously reported [54] but, for comparative
purposes, our data were treated di↵erently. Briefly, for each image, a fluorescent (ORO or and ↵-SMA)
relative intensity (FRI) value was obtained by normalizing the fluorescent binary area (µm2) in the
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fluorescent field to the number of objects in the DAPI field. Rol + PA treatment induced a 30-fold
increase in FRI of lipid droplets in the cytoplasm compared to untreated LX-2 cells (EM).
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LX-2 cell staining with Sirius Red/Fast Green showed purple-stained collagen fibers following
EM and TGF- 1 treatments, clearly indicative of activated cell status [39]. In contrast, quiescent Rol +
PA-treated cells displayed a predominance of green non-collagen proteins (Figure 1a).
The quantitative immunocytochemical analysis of the expression of the intermediate ↵-SMA
filament proteins confirmed what was observed with the collagen staining. Exposing HSCs to TGF- 1
induced a 4-fold increase in the expression of the ↵-isotype of actin, which has been reportedly
associated with early stage liver fibrogenesis in experimental models and to human fibrosis in chronic
liver disease [55] (Figure 1c). The change in FRI from 4.9 (EM sample) to 20.4 (TGF- 1 treatment) proved
the perpetuation of LX-2 cell activation. The increase is known to lead to biochemical modifications
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and render the fibrotic liver ever-increasingly less susceptible to remodeling and repair until a point of
no return is reached [2].
However, the reversibility of HSCs in a TGF- 1-perpetuated activation (pLX-2 cells) was
successfully assessed with Rol + PA. Indeed, pLX-2 cells exposed to Rol + PA showed a notable rise in
the number of lipid droplets visible in bright field and fluorescence images (Figure 2a) corresponding
to a 10-fold increase of the ORO Rol + PA FRI compared to EM (Figure 2b). There was no remarkable
presence of lipid droplets in EM or TGF- 1 p-LX-2 cells (Figure 2b).
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Figure 2. E↵ect of TGF- 1 and Rol + PA on pLX-2 cells. (a) Representative microscopy images of lipid
droplet staining (ORO in bright field and fluorescence; ORO BF; ORO FL) and collagen staining (Sirius
Red/Fast Green in bright field; SR/FG BF). (b) Bar graph showing the ORO fluorescence normalized to
the number of cells in the DAPI field (FRI). Mean ± S.D. (n = 3–6). **** p  0.0001 vs. EM and TGF- 1.
(c) Bar graph showing the ↵-SMA fluorescence normalized to the number of cells in the DAPI field
(FRI). Mean ± S.D. (n = 3). ** p  0.01, *** p  0.001.
After LX-2 cell perpetuation, TGF- 1–treated cells resulted positive for the presence of collagen,
as expected (Figure 2a). Sirius Red/Fast Green staining in bright field revealed purple collagen fibers,
characteristic of activated HSCs. In contrast, predominance of non-collagenous proteins was observed
in green in Rol + PA-treated pLX-2 cells, indicating reversion of the perpetuated cell activation to a
quiescent-like phenotype (Figure 2a).
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The expression of ↵-SMA verified the presence of filaments in EM-treated cells with an FRI
shift from 17.5 (TGF- 1 treatment) to 15 (EM sample) (Figure 2c). Rol + PA treatments asserted the
possibility of reversion with an ↵-SMA FRI of 2. However, compared to the FRI of Rol + PA-treated
naïve LX-2 cells, an FRI of 2 is a 4-fold rise in ↵-SMA expression. This could be explained by a higher
susceptibility of reverted HSCs to recurring fibrogenic stimuli, as observed in previous research [56].
These results show that the phenotype of HSC was successfully modulated by TGF- 1 and Rol
+ PA, and that an informative quantification of typical fibrosis features at the cellular level could be
carried out.
The above-described in vitro protocols were further used to screen the impact of our
own phospholipid-based formulations on activated LX-2 cells, in absence and presence of the
hepatoprotectant silymarin.
3.2. In Vitro Antifibrotic E↵ect of Phospholipid-Based Formulations
Lipid vesicles were produced via the film hydration method as previously reported [38], and
the subsequent extrusion through polycarbonate membranes resulted in large vesicles of expected
size range and PDI (Figure S2). Lipid quantification via HPLC revealed that the lipid content in the
extruded liposomes was approximately 100% (Figures S3 and S4). For the formulations containing
silymarin, an encapsulation e ciency in the range 76–93% was observed (Figures S5 and S6).
Liposomes with a total lipid concentration of 5 mM were applied for LX-2 cell treatments to
maximize the response concerning lipid droplet presence, covering the same 24 h incubation range as
used for Rol + PA-and TGF- 1-treated LX-2 cells.
Percentages of growth and cell viability of LX-2 cells following PCC-based antifibrotic treatments
were first assessed in order to exclude any possible toxicity. As expected, liposomal treatments with and
without silymarin did not impair cell viability (Figure S1). The gain in metabolic activity of the lipids
compared to Rol + PA could be related to changes in mitochondrial activity due to lipid metabolism
and the formation of a high number of lipids droplets [57]. In our study, silymarin liposomes exerted
no remarkable e↵ect on LX-2 cells’ metabolic activity compared to EM-treated cells (Figure S1).
The extent of LX-2 cells’ deactivation to a quiescent-like status was investigated by ORO staining
(Figure 3a,b and Figure S7). After 24 h incubation, DLPC-based formulations induced only a negligible
increase in the number of HSCs lipid droplets in case of pure lipid or DOPC/DLPC-mixed formulations
(Figure 3a). Contrariwise, cytoplasmic lipid droplets could be localized when S80, SMg, and SCa were
used in the formulations (110.4 FRI, 108.3 FRI, 141.5 FRI, respectively) (Figure 3b and Figure S7). Those
values corresponded to a remarkable 41-fold increase in FRI in comparison with that obtained with
EM (2.9 FRI) (Figure 1b) and a 1.4-fold increase even in comparison with the quiescence-inducing Rol
+ PA standard treatment (87 FRI; Figure 1b). When silymarin was formulated with S80, SMg, and
SCa, the ORO staining revealed lipid droplet accumulation in LX-2 cells (Figure 3b and Figure S7) a
49-fold increase in fluorescence originating from the staining fluorescence quantification was detected
(156.5 FRI, 131.7 FRI, 145.4 FRI, respectively) (Figure 3c) with respect to untreated cells (EM, 2.9 FRI;
Figure 1b). The increase in FRI obtained by formulating silymarin in DOPC (41.9 FRI) resulted in only
a 14-fold increase with respect to untreated cells. The co-formulation of a hepatoprotectant with PPCs
resulted in an e cient synergy, reverting myofibroblast-like HSCs to their quiescent-like phenotype
only when S80 was employed. However, the droplet fluorescence of S80 and SMg showed significant
di↵erences toward the FRI from SCa and the formulation with silymarin (Figure 3c). The outstanding
antifibrotic properties of the bioactive S80, SCa, and SMg were significantly improved by the addition
of silymarin, but not in additive or synergistic fashion.
The e↵ect of PPC-based formulations on collagen fibers, resulting from an imbalance between
collagendeposition and reabsorption typical of chronic fibrogenic processes, was then assessed. Treating
LX-2 cells with S80, SMg, or SCa, with or without silymarin, led to the formation of well-defined
green-stained non-collagen fibers (Figure 3b and Figure S7) similarly to that observed with Rol + PA
(Figure 1a). In contrast, when LX-2 cells were treated with DOPC and DOPC–silymarin, purple-stained
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collagen was prevalently visible (Figure 3a,b). Although DOPC/DLPC and DLPC treatments had no
impact on the appearance of lipid droplets, the Sirius Red/Fast Green staining detected the presence
of non-collagen fibers mixed with purple collagenous ones following treatments with these lipids
(Figure 3a), in accordance with previous results [28].
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Figure 3. LX-2 cells directly treated with lipid-based formulations. (a,b) Representative images of ORO
in bright field and fluorescence (ORO BF; ORO FL) and Sirius Red/Fast Green staining in bright field
(SR/FG BF). (c) Bar graph showing the ORO fluorescence normalized to the number of cells in the
DAPI field (FRI). Mean ± S.D. (n = 3–6). * p  0.05, **** p  0.0001. EM, DOPC, and DLPC/DOPC ****
p  0.0001 vs. S80, SMg, SCa, S80–silymarin, SMg–silymarin, SCa–silymarin, and DOPC–silymarin.
DLPC **** p  0.0001 vs. S80, SMg, SCa, S80–silymarin, SMg–silymarin, SCa–silymarin, and *** p 
0.001 vs. DOPC–silymarin (not shown). (d) Bar graph showing the ↵-SMA fluorescence normalized
to the number of cells in the DAPI field (FRI). Mean ± S.D. (n = 3). **** p  0.0001 vs. DLPC, DOPC,
DOPC/DLPC, S80, SMg, SCa, S80–silymarin, SMg–silymarin, SCa–silymarin, and DOPC–silymarin.
All liposomal formulations induced a lower expression of ↵-SMA compared to TGF- 1 and
EM-treated cells, corresponding approximately to a 20-fold decrease of fluorescence (Figure 3d),
confirming the ability of PPC formulations to revert the myofibroblast-like phenotype of naïve LX-2
cells. All treatments resulted in a statistically significant di↵erence (p  0.0001) compared to TGF- 1.
Aiming at assessing the reversibility of HSCs in a perpetuated activation, LX-2 cells were
pre-treated with TGF- 1 for 24 h before exposing them to liposomal formulations.
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pLX-2 cells proved to be still sensitive to quiescence-inducing treatments, as shown by the results
obtained with the ORO staining (Figure 4a,b and Figure S8). Analogously to what was observed
with naïve LX-2 cells, treating pLX-2 cells with S80, SMg, and SCa liposomes prompted a 15-fold
increase in fluorescence (164.5 FRI, 146.1 FRI, and 194.1 FRI, respectively; 10.9 FRI for EM-treated LX-2
cells) (Figure 4c). The synergistic e↵ect induced by S80–silymarin, SMg–silymarin, and SCa–silymarin
(227.3 FRI, 187.3 FRI, and 207.8 FRI, respectively) was slightly lower than that obtained with naïve LX-2
cells (18-fold increase), with DOPC–silymarin formulations (53.9 FRI), resulting also in this case in only
a 5-fold increase with respect to the untreated cells (Figures 3b and 4c). DLPC treatments performed
only slightly better than the DOPC-based formulations (6.6 FRI) (Figure 4c).
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Figure 4. pLX-2 cells treated with lipid-based formulations. (a,b) Representative images of ORO and
Sirius red/Fast green staining in bright field (ORO BF; SR/FG BF) and fluorescence (ORO FL). (c) Bar
graph showing the ORO fluorescence normalized to the number of cells in the DAPI field (FRI). Mean
± S.D. (n = 3–6). * p  0.05, *** p  0.001, **** p  0.0001. Not shown EM, DOPC, and DLPC/DOPC
**** p  . 001 vs. S80, SMg, SCa, S80–silymarin, SMg–silymari , and SCa–silymarin. EM *** p  0.001
vs. il i . PC and DOPC/DLPC * p  0.05 vs. DOPC–silymarin. (d) Bar graph showing
the ↵ fl r alized to the number of cells in the DAPI field (FRI). Mean ± S D. (n = 3).
* p  0.05, ** p  0.01, and * p 
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Overall, these data suggest that PPC formulations are capable of restoring proliferative
myofibroblastic LX-2 cells to a non-dividing, lipid-storing phenotype, typical of quiescent-like HSCs [2],
similarly to what was described for Rol + PA treatments and their induced ADRP upregulation [43].
After LX-2 cell perpetuation, cells treated with S80–silymarin exhibited non-collagenous proteins
(Figure 4b). All the other lipids stained equally for collagenous and non-collagenous proteins
(Figure 4a,b and Figure S8). ↵-SMA expression in perpetuated LX-2 cells treated with PPC-containing
liposomes decreased slightly in comparison with TGF- 1-treated cells (Figure 4d), thus reflecting
a steady partial activated HSC state, as recently suggested in a study elucidating the fate of
HSC/myofibroblasts in experimental fibrosis [58].
3.3. Cell Membrane Motional Order of Adherent LX-2 Cells
The rationale behind the use of two dyes lay in their di↵erent interaction with the bilayer regions.
This di↵erence is highlighted by the incubation time of the two probes used. It has been reported that
the hydrophobic fluorophore DPH is located in the inner region of the phospholipid bilayer, whereas
TMA-DPH is more hindered in translational and rotational motions compared to DPH [59]. Therefore,
DPH estimates the motional order of the inner hydrophobic membrane region, while TMA-DPH senses
changes in motional order at the interface region. TMA-DPH required 10 min to be anchored at the
lipid/water interface, while the hydrophobic DPH required a longer time to be incorporated into the
bilayer (2 h).
In direct treatments, a decrease of DPH anisotropy correspondent to increased motional order
of the inner cell membrane was observed following Rol + PA treatment when compared to the EM,
in accordance with previous reports [60]. As far as phospholipid treatments were concerned, all the
liposomal formulations significantly increased the motional order with respect to that observed with
EM and TGF- 1, except for DOPC (Figure 5a). Specifically, DOPC treatments did not a↵ect the DPH
anisotropy, while a significant treatment-induced decrease (p  0.0001) of the measured anisotropy
coe cients (r) could be observed with DLPC, S80, SMg, SCa, and silymarin liposomes (r value > 0.22)
compared to EM (r value of 0.30). The ability of DLPC to be incorporated into damaged sections of the
cell membrane and to increase membrane fluidity has long been proposed to be the reason behind the
hepatoprotectant action of EPLs, but has never been experimentally investigated [36]. DOPC–silymarin
treatment decreased r significantly from a value of 0.30 (untreated LX-2 cells, EM) to a value of 0.17.
When the amphiphilic TMA-DPHwas used as a fluorescent anisotropy probe, a decrease in r value
from 0.33 of untreated cells (EM) to 0.24 by treating cells directly with DLPC, DOPC, DOPC/DLPC,
and DOPC–silymarin could be observed (Figure 5b). In general, the interaction of the DOPC/DLPC
lipids happened more at the interfacial level, while the PPC seemed to be more active in the inner core
of the plasma membrane.
S80, SMg, and SCa liposomes formulated with silymarin induced a significant decrease of the
DPH r values from 0.33 (TGF- 1-treated) to 0.10 (Figure 5c) in pLX-2 cells. An increased motional
order, although not significant, was also observed with TMA-DPH following the use of the same
lipids (Figure 5d). DLPC, DOPC, DOPC/DLPC, S80, SMg, and SCa had a negligible e↵ect on the
inner membrane, while at the interface region, the e↵ect was similar to the one produced by Rol + PA
(Figure 5d).
Both membrane reporters enabled analysis of the motional order of the cell membrane as a
function of the antifibrotic e↵ect of di↵erent PPC-based formulations. Remarkably, these experiments
were carried out on living adherent LX-2 cells by means of a high-throughput setup (a microplate
reader equipped with polarization filters), expanding on the conventional anisotropy investigations on
biological systems based on suspended cells in quartz cuvettes [60].
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di↵erences in Table S4. (d) Reversion of pLX-2 cells.
4. Conclusions
Herein, we sought to understand the antifibrotic therapeutic utility of phospholipid-based
formulations in deactivating profibrogenic HSCs with an in vitro study based on the main hallmarks
of quiescent and activated HSCs.
The phenotype of HSCs was first modulated by optimizing known treatments with TGF- 1
and Rol + PA. The optimized in vitro protocols were further used for a screening of the impact of
our own phospholipid-based formulations on activated LX-2 cells in absence and presence of the
hepatoprotectant silymarin, as depicted in Scheme 2.
The abundance of lipid droplets, the deficiency of collagen and ↵-SMA, and the rise in membrane
fluidity in LX-2 cells exposed to S80, SMg, or SCa suggested a reversion of HSC transdi↵erentiation.
These modulating e↵ects were synergistically enhanced by co-formulating the hepatoprotectant
silymarin with S80. DOPC, DLPC, and DOPC/DLPC induced an increase in inner membrane fluidity,
but their contributions to lipid droplet formation, collagen reduction, and ↵-SMA was negligible.
DLPC-based formulations enhanced the breakdown of collagen, as previously reported, but did not
seem to compete with the PPC-containing S80 family.
Although further biochemical studies are required, liposomes formulated with the natural
phospholipid S80 and its new complexes with Mg and Ca salts, SMg and SCa, show high potential for
Pharmaceutics 2019, 11, 676 15 of 18
long-term antifibrotic therapies either alone or in combinationwith hepatoprotectants such as silymarin.
Thus, in a follow-up investigation, these three PPCs will be employed as the main components of oral
dosage forms and investigated in relevant experimental models of fibrosis.
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